thromboDx BV awarded prestigous NGI Preseed Grant

Posted on

Dr. Thomas Wurdinger from thromboDx BV was awarded a prestigous Preseed grant: Diagnosing cancer from thrombocytes for personalized applications. Summary: The development of diagnostics platforms that provide biomarkers which are highly predictive for diagnosing, monitoring and stratifying cancer patients are key instruments in personalized medicine. Thrombocytes (blood platelets) are a novel source of high-quality tumor-derived RNA. This finding allows adequate development of a platform technology for isolation and identification of tumor-derived (mutant) RNAs in blood platelets and thereby addressing current requirements for companion diagnostics as the method is easy, cost-effective, and non-invasive. In addition, the use of blood platelets as a biomarker source for prenatal dispositions, infectious disease, and cardiac and neurodegenerative disease, is in progress.

Comments are closed.